ArticleFrontiers in oncology2025
Retrospective analysis of the efficacy and safety of anlotinib plus sintilimab (anti-PD-1) as maintenance therapy in advanced pediatric solid tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced solid tumors in children have limited maintenance treatment options. This study assessed the effectiveness and safety of anlotinib in conjunction with sintilimab as maintenance therapy for advanced pediatric solid tumors in real-world settings. Methods: This single-institution retrospective study was conducted at the Affiliated Cancer Hospital of Zhengzhou University from November 2019 to October 2023. Forty-six patients with advanced pediatric solid tumors who achieved partial response or stable disease following first-line (22/46) or second-line (24/46) chemotherapy subsequently received maintenance therapy with a combination of anlotinib and sintilimab. The primary endpoint was median progression-free survival (mPFS). Secondary endpoints included median overall survival (mOS), disease control rate (DCR), and safety. Results: After a median follow-up of 21.8 months (95% CI, 16.5-27.1), the mPFS was 25.3 months (95% CI, 7.0-43.6) in the first-line treatment group and 13.3 months (95% CI, 7.2-19.4) in the second-line treatment group. The mOS in the first-line and second-line treatment groups was 38.2 months (95% CI, 22.2-54.1) and 16.5 months (95% CI, 12.6-20.4), respectively. The DCR was 50.0% (11/22; 95% CI, 28-72) in the first-line group and 37.5% (9/24; 95% CI, 19-59) in the second-line group. Most treatment-related adverse events were grade 1-2. The most common grade 3-4 adverse event was anemia (2/46, 4.3%). Conclusion: These results indicate that maintenance therapy using anlotinib combined with sintilimab could be a safe and effective treatment option for advanced pediatric tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.